ARTICLE | Clinical News

Atragen tretinoin: Phase II

December 11, 2000 8:00 AM UTC

In a Phase II trial of 65 patients with relapsed or refractory NHL or CTCL, a 120 mg/m 2 dose of Atragen given intravenously every other day over 28 days gave a clinical response in 17 of 57 evaluable...